Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vertex Pharmaceuticals, Inc shares valued at $7,178 were sold by ALTSHULER DAVID on Nov 15 ’24. At $478.56 per share, ALTSHULER DAVID sold 15 shares. The insider’s holdings dropped to 25,813 shares worth approximately $10.24 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ALTSHULER DAVID purchased 15 shares, netting a total of over 7,178 in proceeds.
Before that, WAGNER CHARLES F JR had sold 3,000 shares from its account. In a trade valued at $1,554,810, the EVP & Chief Financial Officer traded Vertex Pharmaceuticals, Inc shares for $518.27 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $17.51 million.
As published in a research note from Oppenheimer on December 19, 2024, Vertex Pharmaceuticals, Inc [VRTX] has been rated down from an Outperform to a Perform. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early December. As of November 14, 2024, Citigroup has initiated its “Buy” rating for VRTX. Earlier on October 16, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector perform” for VRTX stock.
Analyzing VRTX Stock Performance
During the last five days, there has been a drop of approximately -14.54%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have dropped approximately -2.52%. Shares of the company reached a 52-week high of $519.88 on 11/08/24 and a 52-week low of $377.85 on 12/19/24. A 50-day SMA is recorded $472.35, while a 200-day SMA reached $457.71. Nevertheless, trading volume fell to 8.2 million shares from 1.74 million shares the previous day.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 381.65, which, if violated, would cause prices to drop to 366.65. In the upper region, resistance lies at 407.84. The next price resistance is at 419.03. RSI (Relative Strength Index) is 23.70 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -21.46, which suggests the price will decrease in the coming days. Percent R is at 80.94%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
